Beyond immunostimulation, alterations in circulating EV profiles offer clinically relevant biomarkers: in rheumatoid arthritis, CD14+ HLA-DR+ EVs reflect antigen-presenting-cell activation (15), and plasma RANKL+ EVs correlate with bone metastases and skeletal-related events (16). Here, CD14 is linked to rheumatoid arthritis.